Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Covid-19 has exposed the limits of the pharmaceutical market model
No Vaccine in Sight
The U.S. government contributed research to a Gilead remdesivir patent — but didn’t get credit
Covid Seen as Tipping Point to Lower Drug Prices, Patent Sharing
Coronavirus puts Big Pharma’s IP regime to the test
Coronavirus crisis may bring out old tool in disease fights: suspension of drug patents
Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism
In rare move, Gilead gives up ‘orphan’ status for experimental coronavirus drug
Ford School hosts conversation on drug patent system reform
Why are Drug Prices So High? Investigating the outdated US patent system